- Shanghai Active Technology (主动科技) announced on August 3, 2026 that it closed a RMB 330 million (~$45.8 million) angel round, which 36Kr and Gasgoo describe as the largest single angel round in China’s brain-computer interface sector to date.12
- The round was led by CAS Star (中科创星), with participation from Lenovo Star, Joy Capital, Daotong Investment, Inno Angel Fund, BGI Songhe Life Science Fund, Jiufeng Capital, and Jiadao Capital.1
- The company, founded only in February 2026, is building a full-link invasive BCI platform spanning flexible electrodes, dedicated chips, decoding algorithms, and system integration across three product lines: motor, visual, and emotional interfaces.2
- Its lead product, Tianshu, is a 1,024-channel invasive motor BCI targeting stroke, spinal cord injury, and ALS indications; it has obtained a type inspection report and is preparing to launch clinical trials.2
- If trials proceed as planned, Active Technology would reportedly be the first in China to conduct clinical trials for a 1,024-channel invasive BCI system.2
- Proceeds will fund facility expansion, equipment upgrades, clinical trial advancement, and team growth as the company races to commercialize invasive BCI technology just six months after incorporation.12